Of note, this phenomenon appears to be eliminated by the administration of post-transplantation cyclophosphamide for the prevention of GVHD, suggesting that it is at least partially mediated by DNMT3A-mutated donor T-cells, the function of which is altered by cyclophosphamide (58, 59). This evidence concerns the gene DNMT3A and graft versus host disease.